专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09193765B2 Melk epitope peptides and vaccines containing the same 有权
标题翻译： Melk表位肽和含有它们的疫苗
公开(公告)号：US09193765B2
公开(公告)日：2015-11-24
申请号：US14171532
申请日：2014-02-03
申请人： Oncotherapy Science, Inc.
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： C07K14/00 , C07K7/06 , C07K14/47 , A61K38/00 , A61K39/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K7/06 , C07K14/4747 , C12N5/0638 , C12N9/12 , C12N2502/11 , C12N2510/00 , C12Y207/10002 , C12Y207/11001
摘要： According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
摘要翻译：根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。本发明的药剂包括疫苗。

2. 发明申请

US20150315239A1 METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES 审中-公开
标题翻译：通过管理WDRPUH EPITOPE肽诱导免疫应答的方法
公开(公告)号：US20150315239A1
公开(公告)日：2015-11-05
申请号：US14805424
申请日：2015-07-21
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K7/06 , A61K39/00
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1764 , A61K39/0011 , C07K14/47 , C07K14/4748 , C12N5/0638 , C12N5/0639
摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.
摘要翻译：本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。本发明的肽也可以用作疫苗。

3. 发明授权

US09675680B2 MELK epitope peptides and vaccines containing the same 有权
公开(公告)号：US09675680B2
公开(公告)日：2017-06-13
申请号：US14924546
申请日：2015-10-27
申请人： Oncotherapy Science, Inc.
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K7/06 , C12N5/0783 , C12N9/12
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K7/06 , C07K14/4747 , C12N5/0638 , C12N9/12 , C12N2502/11 , C12N2510/00 , C12Y207/10002 , C12Y207/11001
摘要： According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.

4. 发明授权

US08759481B2 Peptide vaccines for cancers expressing tumor-associated antigens 失效
公开(公告)号：US08759481B2
公开(公告)日：2014-06-24
申请号：US13744354
申请日：2013-01-17
申请人： Oncotherapy Science, Inc.
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： C07K16/00
CPC分类号： C07K4/12 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/572 , C07K7/06 , C07K14/47 , G01N2500/00
摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

5. 发明授权

US10711047B2 CDCA1 epitope peptides and vaccines containing the same 有权
公开(公告)号：US10711047B2
公开(公告)日：2020-07-14
申请号：US15176444
申请日：2016-06-08
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K39/00 , C07K14/47 , C12N5/0783 , C07K7/06 , A61K38/00
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

6. 发明授权

US09745343B2 Method of inducing an immune response by administering WDRPUH epitope peptides 有权
公开(公告)号：US09745343B2
公开(公告)日：2017-08-29
申请号：US14805424
申请日：2015-07-21
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K38/04 , A61K38/08 , C07K7/06 , A61K39/00 , C07K14/47 , A61K38/17 , C12N5/0783 , C12N5/0784 , A61K38/00
CPC分类号： C07K7/06 , A61K38/00 , A61K38/1764 , A61K39/0011 , C07K14/47 , C07K14/4748 , C12N5/0638 , C12N5/0639
摘要： The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

7. 发明授权

US09446106B2 NEIL3 peptides and vaccines including the same 有权
公开(公告)号：US09446106B2
公开(公告)日：2016-09-20
申请号：US14689302
申请日：2015-04-17
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura , Yoichi Furukawa
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , A61K39/39 , C12N9/88
CPC分类号： C07K14/4748 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/53 , A61K2039/572 , C12N9/88 , C12Y402/99018 , Y02A50/396
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

8. 发明授权

US09403890B2 HJURP peptides and vaccines including the same 有权
标题翻译： HJURP肽和疫苗包括相同
公开(公告)号：US09403890B2
公开(公告)日：2016-08-02
申请号：US14205163
申请日：2014-03-11
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K7/00 , A61K38/08 , C07K14/47 , C07K7/06 , C07K16/18 , A61K35/12 , A61K38/00 , A61K39/00
CPC分类号： C07K14/4748 , A61K35/12 , A61K38/00 , A61K39/00 , C07K7/06 , C07K16/18
摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
摘要翻译：本文描述了衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗。本发明的肽包括上述氨基酸序列及其修饰形式，只要它们保留原始序列所需的细胞毒性T细胞诱导能力即可。还提供了编码肽的核酸以及包括任何肽或核酸的药剂，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物可用于治疗癌症，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食道癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

9. 发明申请

US20160200764A1 PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS 审中-公开
标题翻译：用于表达肿瘤相关抗原的癌症的肽疫苗
公开(公告)号：US20160200764A1
公开(公告)日：2016-07-14
申请号：US14989741
申请日：2016-01-06
申请人： OncoTherapy Science, Inc.
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： C07K7/06 , A61K39/00
CPC分类号： C07K4/12 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/572 , C07K7/06 , C07K14/47 , G01N2500/00
摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
摘要翻译：本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽，提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。含有这些肽中的一种或多种的活性成分的癌症。本发明的肽可作为疫苗进一步发挥作用。

10. 发明申请

US20140141027A1 PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS 审中-公开
公开(公告)号：US20140141027A1
公开(公告)日：2014-05-22
申请号：US14079144
申请日：2013-11-13
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： C07K7/06
CPC分类号： C07K4/12 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/572 , C07K7/06 , C07K14/47 , G01N2500/00
摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式